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Abstract
Background: Transport of fatty acids within the cytosol of adipocytes and their subsequent
assimilation into lipid droplets has been thoroughly investigated; however, the mechanism by which
fatty acids are transported across the plasma membrane from the extracellular environment
remains unclear. Since triacylglycerol-rich lipoproteins represent an abundant source of fatty acids
for adipocyte utilization, we have investigated the expression levels of cell surface lipoprotein
receptors and their functional contributions toward intracellular lipid accumulation; these include
very low density lipoprotein receptor (VLDL-R), low density lipoprotein receptor-related protein
(LRP), and heparan sulfate proteoglycans (HSPG).
Results: We found that expression of these three lipoprotein receptors increased 5-fold, 2-fold,
and 2.5-fold, respectively, during adipocyte differentiation. The major proteoglycans expressed by
mature adipocytes are of high molecular weight (>500 kD) and contain both heparan and
chondroitin sulfate moieties. Using ligand binding antagonists, we observed that HSPG, rather than
VLDL-R or LRP, play a primary role in the uptake of DiI-lableled apoE-VLDL by mature adipocytes.
In addition, inhibitors of HSPG maturation resulted in a significant reduction (>85%) in intracellular
lipid accumulation.
Conclusions: These results suggest that cell surface HSPG is required for fatty acid transport
across the plasma membrane of adipocytes.
Background
The adipocyte plays a central role in overall metabolic reg-
ulation serving as a storage depot for fatty acids and as an
endocrine cell to regulate energy utilization and feeding
behavior [1,2]. The mass of adipose tissue is maintained
by a well-controlled balance of cell proliferation (hyper-
plasia) and increase in fat cell size (hypertrophy). Con-
tributing to adipocyte hypertrophy is the assimilation of
fatty acids into cytosolic triacylglycerol-rich lipid droplets.
Fatty acids enter the adipocyte through the plasma mem-
brane, are converted to their acyl-CoA derivatives and
transported through the cytosol with the assistance of
fatty acid binding proteins due to the lipophilic nature of
the fatty acid hydrocarbon chain [3,4]. They are then reas-
sembled into triacylglycerol units by acyltransferases. The
intracellular lipid droplet that forms from the coalescence
of triacylglycerols has recently been shown to associate
with regulators of membrane trafficking in addition to
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gesting a complex and dynamic role deserving of the
name adiposome [5].
Extracellular fatty acids that are available for adipocyte
uptake are either 1) associated with circulating albumin,
2) hydrolyzed from triacylglycerol-rich lipoprotein parti-
cles by lipoprotein lipase, or 3) in the form of VLDL par-
ticles which can be directly internalized by adipocyte
lipoprotein receptors. In the circulation, VLDL represents
the major source of fatty acids for peripheral tissues in the
form of triacylglycerols and provides a concentrated
source of esterified fatty acids. It is interesting that in light
of the well studied processes of cytosolic transport and
assimilation of free fatty acids into triacylglycerol-rich
storage droplets, the mechanism of transport of fatty acids
across the adipocyte plasma membrane remains contro-
versial. Two mechanisms, which are not mutually exclu-
sive, have been proposed: one involves passive diffusion
across the plasma membrane [6,7], the other requires pro-
tein-mediated transport [8,9]. Passive diffusion, which
requires protonation of the fatty acid prior to entering the
bilayer, has long been regarded as the major pathway for
uptake of fatty acids by cells. However, recent kinetic data
suggest that passive diffusion, while sufficient for cells
with relatively low metabolic rates, is likely to be insuffi-
cient for cells with high fatty acid utilization such as skel-
etal muscle and adipose [10-12]. Moreover, the role of
fatty acid-albumin complexes as a significant source of
diffusible free fatty acids has recently been questioned, as
evidence indicates that a significant transfer of fatty acids
from albumin occurs only at very high and non-physio-
logical fatty acid to albumin ratios [13,14]. Protein-medi-
ated transport of fatty acids has been investigated using
fatty acid binding and uptake studies [15,16]. These
results show that fatty acid permeation demonstrates con-
centration-dependent, nonlinear saturation kinetics with
a Km of transport of ~7 nM [9]. Moreover, uptake of long-
chain fatty acids (>18 carbons) was competable [17,18],
further suggesting a receptor-mediated process.
Several cell surface proteins are expressed by adipocytes
which potentially contribute to receptor-mediated uptake
of extracellular fatty acids; these include CD36, fatty acid
transport protein-1 (FATP1), very low density lipoprotein
receptor (VLDL-R), low density lipoprotein receptor-
related protein (LRP), and heparan sulfate proteoglycans
(HSPG). CD36 is a cell surface glycoprotein that binds
long-chain fatty acids with high affinity and demonstrates
a subcellular distribution that is consistent with a role in
fatty acid transport across the plasma membrane [19-23].
Following the induction of pre-adipocyte 3T3-L1 cells,
CD36 expression increases [24] with a concomitant
increase in fatty acid uptake. In vivo studies corroborate
these observations as uptake of long-chain fatty acids is
impaired in CD36 knock-out mice [25] or when CD36
expression is reduced by anti-sense RNA treatment [22].
Although these data indicate a significant role for CD36 in
long-chain fatty acid uptake, the data further suggest that
it is not sufficient to account for the entirety of fatty acid
uptake by adipocytes since the absence of CD36 reduces
uptake by only 50% [25]. FATP1 is a 71 kD transmem-
brane protein and the major FATP family member
expressed in adipocytes [26]. In adipocytes, insulin is
known to induce the translocation of FATP1 from a peri-
nuclear compartment to the plasma membrane [27]. Sim-
ilar to CD36, FATP1 expression enhances the uptake of
fatty acids [26,28].
Studies using a VLDL-R knock-out animal model have
suggested a role for this receptor in the accumulation of
fatty acids by adipose tissue; mice lacking VLDL-R demon-
strate only modest weight gain and a reduction in adipose
tissue mass when placed on a high-fat diet [29]. VLDL-R
mRNA is known to increase ~3–5-fold during adipocyte
differentiation [30], suggesting that it may play a critical
role in adipocyte physiology. The LRP is also expressed by
adipocytes [31-33] and like VLDL-R can bind and inter-
nalize apoE-enriched VLDL particles [34,35]. However, its
role in lipid accumulation by adipocytes has not been
investigated. HSPG have been well characterized in their
ability to bind and internalize apoE-enriched VLDL [36-
38], as well as localize lipases to the cell surface through
high affinity binding [39,40]. HSPG have also been
shown to play a significant role in the hepatic clearance of
lipoprotein, however, like LRP, no studies to date have
investigated their role in intracellular lipid accumulation
by adipocytes.
To better understand the process of fatty acid transport
across the plasma membrane of adipocytes, we have
examined the expression levels and functional contribu-
tions of lipoprotein receptors, VLDL-R, LRP and HSPG
toward intracellular lipid accumulation. Our findings sug-
gest that cell surface HSPG play an essential role in fatty
acid uptake and intracellular lipid accumulation in
adipocytes.
Results
VLDL-R and LRP protein expression increases during 
adipocyte differentiation
Since members of the LDL receptor family are known to
play a predominant role in the uptake of lipoproteins, we
chose to examine the protein expression levels of VLDL-R
and LRP during adipocyte differentiation using 3T3-L1
cells [41], which are a well-established in vitro model for
adipocyte differentiation [42,43]. 3T3-L1 cells were incu-
bated with or without differentiation agents (dexametha-
sone, 3-isobutyl-1-methylxanthine, and insulin) and total
protein extracts were immunoblotted with antibodiesPage 2 of 15
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cific chaperone, receptor associated protein (RAP) (Fig.
1). Densitometric analysis of the resulting immunoblots
indicated that VLDL-R expression increased by ~5-fold
over non-differentiated, control cells. LRP expression
demonstrated a more modest increase of ~2-fold over
control cells. RAP showed no difference in expression
between treated and non-treated cells, thus serving as a
useful internal loading control. These results are consist-
ent with previous studies which have shown an increase
in mRNA levels during adipocyte differentiation for
VLDL-R (3–5-fold) [30] and LRP (1.5 to 2-fold) [31].
RAP, besides being an exocytic chaperone for members of
the LDL receptor family, is also a high affinity ligand for
most, if not all, members of the family [44,45]. This prop-
erty is useful for evaluating specific receptor binding and
internalization activities by cells. Cell surface expression
of LDL receptor family members was compared between
control, non-treated 3T3-L1 cells and differentiated cells
by incubating with 125I-RAP at 4°C (Fig. 2A). Differenti-
ated cells were found to bind ~7-fold more 125I-RAP than
non-treated control cells. This increase in receptor expres-
sion, as measured by ligand binding, is quantitatively con-
sistent with that measured by immunoblotting. When
Expression of VLDL-R and LRP increases following adipocyte differentiationFigure 1
Expression of VLDL-R and LRP increases following adipocyte differentiation. Pre-adipocyte 3T3-L1 cells were incu-
bated for 4 d in the presence (+) or absence (-) of 100 ng/ml dexamethasone, 100 µg/ml 3-isobutyl-1-methylxanthine, and 1 µg/
ml insulin, followed by 1 µg/ml insulin for an additional 4–8 d. Total cellular protein was obtained by detergent extraction, equal 
amounts of protein (20 µg/lane) were separated by SDS-PAGE and immunoblotted with anti-VLDL-R polyclonal IgG (4 µg/ml), 
or anti-LRP (1:2000) or anti-RAP (1:2000) antisera. The chemiluminescence image was quantitated by densitometry. Values 
obtained for non-treated cells were assigned as 100% for comparison with treated cells. Data shown is representative of 3 sep-
arate experiments.Page 3 of 15
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receptor internalization, we found that differentiated
adipocytes internalized ~2-fold more 125I-RAP than con-
trol 3T3-L1 cells (Fig. 2B). Together, these results indicate
that levels of both VLDL-R and LRP are increased at the
cell surface resulting in increased receptor internalization
activity in differentiated adipocytes.
Sulfated proteoglycan levels are increased in 
differentiated adipocytes
Although HSPG are known to play a critical role in bind-
ing of lipoproteins to the cell surface [46,47] and addi-
tionally serve as a primary interaction site for LPL [48,49],
little evidence has been reported as to their function in
lipid accumulation by adipocytes. To begin to characterize
their role in adipocyte growth, we first examined changes
in overall proteoglycan synthesis during adipocyte differ-
entiation. 3T3-L1 preadipocytes and differentiated adi-
pocytes were incubated with 35SO4 to label
glycosaminoglycan moieties. Cell lysates were prepared
by extracting with urea and radiolabeled proteoglycans
were analyzed by anion exchange chromatography. As
shown in Fig. 3A, the amount of 35SO4-labeled proteogly-
can recovered from mature adipocytes was ~2.5-fold
greater than that extracted from pre-adipocytes indicating
that proteoglycan synthesis is augmented during differen-
tiation. When the chromatographic fractions were sepa-
rated by SDS-PAGE, interestingly, we found primarily
high molecular weight species of proteoglycans in extracts
from either pre-adipocytes or mature adipocytes (Fig. 3B).
To analyze the composition of the high molecular weight
proteoglycan species synthesized by mature adipocytes,
we incubated the chromatographically enriched material
with heparinase I, chondroitinase ABC, or a mixture of
both enzymes followed by size fractionation (Fig. 3C).
With no enzymatic digestion, the material eluted at the
exclusion limit of the column. Treatment with heparinase
I reduced peak fractions 6–8 by ~15% and yielded a lower
molecular weight product that eluted between fractions
10–14. By contrast, chondroitinase ABC treatment
reduced the high molecular weight, peak fractions 6–8 by
~65–70% and generated mostly low molecular weight
products eluting between fractions 11–15. The high
molecular weight material remaining after chondroitinase
ABC treatment likely consists primarily of heparan sulfate
moieties. This was confirmed by treating the enriched pro-
teoglycans with both heparinase I and chondroitinase
ABC which resulted in essentially a quantitative shift of
labeled material from high molecular weight fractions to
fractions consisting of primarily lower molecular weight
products. These data provide us with two important
observations; 1) major proteoglycan species synthesized
by mature adipocytes are of very high molecular weight,
and 2) this proteoglycan structure consists mostly of
chondroitin sulfate glycosaminoglycans with a smaller
percentage of heparan sulfate moieties.
HSPG participate in the uptake of DiI-labeled 
apolipoprotein E-enriched VLDL by adipocytes
The extent to which extracellular lipoproteins contribute
to lipid accumulation by adipocytes has not been fully
established. A recent study suggests that uptake of VLDL
by adipocytes stimulates intracellular lipid accumulation
[50]. To identify if either HSPG or LDL receptor family
members play a role in this process, we incubated mature
adipocytes with DiI-labeled apoE-enriched VLDL in the
Differentiated adipocytes bind and internalize more RAP than pre-adipocytesFigu  2
Differentiated adipocytes bind and internalize more 
RAP than pre-adipocytes. Pre-adipocyte 3T3-L1 cells and 
differentiated adipocytes were incubated with 125I-RAP (500 
ng/ml) in the presence (hatched bars) or absence (solid bars) 
of unlabeled RAP (20 µg/ml) at 4°C for 3 h (A) or 37°C for 3 
h (B). For 4°C incubations, bound ligand was solubilized and 
directly quantitated by scintillation counting. For 37°C incu-
bations, culture media was processed for trichloroacetic acid 
(TCA) precipitation and soluble radioactivity, representing 
degraded ligand, was quantitated by scintillation counting.Page 4 of 15
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Adipocyte differentiation results in increased synthesis of a high molecular weight proteoglycan that consists 
of a mixture of heparan and chondroitin sulfate glycosaminoglycan moieties. Pre-adipocyte 3T3-L1 cells and differ-
entiated adipocytes were incubated for 20 h with 35SO4 (125 µCi/ml). (A), cells were lysed with 8 M urea and proteins were 
fractionated by anion exchange chromatography as described in Methods. Radioactivity in each fraction was determined by 
scintillation counting. (B), fractions from (A) were separated by 7% SDS-PAGE and subjected to phosphorimager analysis 
(upper panel, pre-adipocytes; lower panel, adipocytes). (C), 35SO4-labeled proteoglycans, enriched by anion exchange chroma-
tography, were incubated with or without heparinase I (5 Units/ml), chondroitinase ABC (5 Units/ml), or both enzymes for 20 
h at 37°C. Labeled material was then fractionated by size exclusion chromatography and fractions were assessed by scintilla-
tion counting.Page 5 of 15
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Heparin, but not RAP, competes for DiI-apoE-VLDL uptake by adipocytes. Differentiated adipocytes were cultured 
on glass coverslips and incubated with DiI-labeled apoE-VLDL (4 µg/ml) in the presence or absence (upper panel) of either 
heparin (500 µg/ml, middle panel) or RAP-GST (50 µg/ml, lower panel) at 37°C for 3 h. Cells were then fixed and processed 
for fluorescence microscopy. Left panels, phase contrast image; right panels, rhodamine filter set (550 nm excitation-573 nm 
emission). Magnification, 630×.Page 6 of 15
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activity) or RAP (to inhibit VLDL-R and LRP function) and
visualized the cells by fluorescence microscopy (Fig. 4). In
the absence of potential competitors, mature adipocytes
readily internalized DiI-apoE-VLDL into small cytosolic
vesicles (upper panel). Incubation with RAP showed little
or no effect on DiI-apoE-VLDL uptake (lower panel).
However, incubation with heparin significantly inhibited
intracellular accumulation of DiI-apoE-VLDL (middle
panel) indicating that HSPG, rather than VLDL-R or LRP,
play a major role in apoE-VLDL internalization.
HSPG are necessary for intracellular lipid accumulation in 
mature adipocytes
4-methylumbelliferyl-β-D-xylopyranoside (4-MUmb)
and p-nitrophenyl-β-D-xylopyranoside (pNP-Xyl) are rea-
gents that can serve as alternative acceptors within cells for
heparan sulfate moieties and are thus able to compete for
heparan sulfate chain addition to proteoglycan core pro-
teins [51,52]. The bare proteoglycan core proteins that
result from this treatment traverse to the plasma mem-
brane but are devoid of any heparan sulfate gly-
cosaminoglycan modifications. This in effect removes
heparan sulfate proteoglycan functionality from the sur-
face of treated cells and permits an examination of HSPG
contributions to cell function. To ensure that these rea-
gents do not interfere with the events of adipocyte differ-
entiation, we treated 3T3-L1 pre-adipocytes with 4-
MUmb or pNP-Xyl concurrently with the addition of dif-
ferentiation reagents and examined the expression levels
of proteins known to increase during adipocyte forma-
tion, namely VLDL-R, LRP, CD36/FAT [21], and leptin
[53]. By immunoblot analysis, we found that the expres-
sion levels of these proteins were comparable between
treated and non-treated cells (Fig. 5A). Since lipoprotein
lipase (LPL) synthesis is also known to increase following
3T3-L1 differentiation [54,55], we measured enzymatic
activity of LPL in the culture supernatants of induced and
non-induced 3T3-L1 cells and compared these results
with those obtained from induced 3T3-L1 cells treated
with either 4-MUmb or pNP-Xyl (Fig. 5B). As expected,
conversion of 3T3-L1 pre-adipocytes to mature adipocytes
resulted in ~5–6-fold increase in LPL activity. Importantly,
no significant difference in LPL activity was noted
between normal mature adipocytes and those treated with
either 4-MUmb or pNP-Xyl. These data indicate that
expression of these proteins is unaffected by inhibited
proteoglycan maturation and, importantly for our pur-
poses, that addition of 4-MUmb or pNP-Xyl to cells does
not prevent adipocyte differentiation.
To determine if HSPG are involved in intracellular lipid
accumulation by mature adipocytes, we assessed cytosolic
lipid droplet formation in induced 3T3-L1 cells following
treatment with either 4-MUmb or pNP-Xyl. Again 3T3-L1
Inhibitors of HSPG maturation have no effect on adipocyte differentiationFigure 5
Inhibitors of HSPG maturation have no effect on adi-
pocyte differentiation. 3T3-L1 pre-adipocytes were incu-
bated with or without 3 mM pNP-Xyl or 4-MUmb 
concurrently with differentiation reagents for 4 d. Media was 
then changed to include just insulin with or without 3 mM 
pNP-Xyl or 4-MUmb for an additional 4–8 d. (A), cell lysates 
were immunoblotted with anti-VLDL-R mAb (1:50, culture 
supernatant), anti-LRP antisera (1:2000), or anti-CD36 IgG (5 
µg/ml). For anti-leptin, proteins in culture supernatant were 
concentrated 10-fold by acetone precipitation prior to SDS-
PAGE fractionation and immunoblotted with anti-leptin IgG 
(2 µg/ml). (B), following differentiation and xyloside treat-
ment, cells were cultured for 16 h in serum-free, phenol red-
free media. Culture supernatants were then assayed for LPL 
enzymatic activity as described in Methods. No significant dif-
ference was found in LPL levels between adipocytes treated 
with xylosides and untreated adipocytes (asterisk, p-value 
<0.01).Page 7 of 15
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concurrently with the addition of differentiation reagents
and intracellular lipid accumulation was assessed by Oil
Red O staining. Upon Oil Red staining, untreated mature
adipocytes demonstrated large intracellular droplets; the
characteristic morphologic feature of cytosolic lipid accu-
mulation (Fig. 6A, left panel). By contrast, adipocytes
treated with either 4-MUmb or pNP-Xyl showed little
staining by the lipophilic dye (Fig. 6A, middle and right
panels, respectively). To quantitate this effect, cell-associ-
ated lipophilic dye was extracted and measured by spec-
trophotometry (Fig. 6B). Treatment of adipocytes with 4-
MUmb or pNP-Xyl resulted in ~6–7-fold decrease in lipid
accumulation. Moreover, adipocytes treated with varying
concentrations of 4-MUmb or pNP-Xyl demonstrated a
concentration-dependent effect of these HSPG inhibitors
on intracellular lipid accumulation (Fig. 7). Together,
these data indicate that HSPG play an essential role in
lipid accumulation by adipocytes.
Discussion
Intracellular lipid accumulation is a hallmark event of adi-
pocyte development and the major factor in adipocyte
hypertrophy. This prompted us to investigate the molecu-
lar mechanism by which adipocytes take up extracellular
lipid components. In the present study, we provide new
information on the expression levels and functional activ-
ities of certain cell surface receptors in mature adipocytes
that are known to play primary roles in lipoprotein
processing and clearance. These receptors have been
extensively studied in liver, the major organ for dietary
lipoprotein clearance [56], however little information is
available regarding their function in lipid accumulation
by adipocytes. Using 3T3-L1 cells, which is a well estab-
lished model of adipocyte differentiation, we show that
protein expression of the lipoprotein receptors, VLDL-R
and LRP, is increased during adipocyte differentiation, 5-
fold and 2-fold, respectively. This increase is consistent
with previous studies reporting increases in mRNA levels
for these proteins [30,31]. The comparable increase
between mRNA and protein levels also suggests that the
overall increase in receptor expression following differen-
tiation is primarily due to an increase in transcription with
little or no post-transcriptional regulation. We also dem-
onstrate that both pre-adipocytes and mature adipocytes
express one major form of sulfated proteoglycan with a
Reduction of cell surface heparan sulfate glycosaminoglycans signifi antly reduces intrac llular lipid accumulation in adipo ytesFig re 6
Reduction of cell surface heparan sulfate gly-
cosaminoglycans significantly reduces intracellular 
lipid accumulation in adipocytes. 3 mM 4-MUmb or 
pNP-Xyl was added to 3T3-L1 cells concurrently with differ-
entiation reagents as in Fig. 5. Cells were then fixed with 10% 
formaldehyde, stained with 0.1% Oil Red O and photo-
graphed with phase contrast optics (A; magnification, 400×). 
(B), after image capture, cell-associated Oil Red O was 
extracted with 0.1 N HCl and dye was quantitated by spec-
trophotometry. Asterisk indicates a statistically significant dif-
ference compared to untreated adipocytes (p < 0.01).
Reduction in intracellular lipid accumulation in adipocytes by h paran sulfate inhibitors is con entration-dependentFig e 7
Reduction in intracellular lipid accumulation in adi-
pocytes by heparan sulfate inhibitors is concentra-
tion-dependent. 4-MUmb (solid bars) or pNP-Xyl (hatched 
bars) was added to 3T3-L1 cells at the indicated concentra-
tions concurrently with differentiation reagents as in Fig. 5. 
Cells were then fixed with 10% formaldehyde, stained with 
0.1% Oil Red O, and cell-associated lipophilic dye was 
extracted with 0.1 N HCl and quantitated by spectropho-
tometry. Data shown represents an average of three 
experiments.Page 8 of 15
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species of proteoglycan increases ~2.5-fold during differ-
entiation and appears to contain both heparan and chon-
droitin sulfate glycosaminoglycans. Furthermore, we
found that uptake of DiI-labeled VLDL by adipocytes is
inhibited by heparin, but not RAP, suggesting that in adi-
pocytes HSPG play a greater role in lipoprotein uptake
than do members of the LDL receptor family. Since VLDL
is a major carrier of fatty acids in the form of
triacylglycerols, these data suggest to us that HSPG may
provide a mechanism for facilitating the uptake of fatty
acids and significantly contribute to intracellular lipid
accumulation. To address this hypothesis, we treated adi-
pocytes with 4-methylumbelliferyl-β-D-xylopyranoside
and p-nitrophenyl-β-D-xylopyranoside, which are com-
petitive inhibitors of heparan sulfate chain addition, to
prevent the synthesis of functional cell surface HSPG mol-
ecules. We found this treatment to effectively block
intracellular lipid accumulation in adipocytes without
affecting adipocyte differentiation.
These findings offer a novel observation that cell surface
HSPG appear to be essential for lipid accumulation and
lipid droplet formation in adipocytes. However, this
observation also raises the question as to the exact role of
HSPG in the transport of fatty acids across the adipocyte
plasma membrane. Based on the results presented in this
study and those reported elsewhere, we have drawn a test-
able model to define how HSPG contribute to
intracellular lipid accumulation by adipocytes (Fig. 8).
Model for HSPG activity contributing to fatty acid uptake and intracellular lipid accumulation in adipocytesFigure 8
Model for HSPG activity contributing to fatty acid uptake and intracellular lipid accumulation in adipocytes. 
Cell surface heparan sulfate proteoglycans (HSPG) serve as primary binding sites for apoE-enriched VLDL (apoE-VLDL) and 
lipoprotein lipase (LPL) on adipocytes. Localization of apoE-VLDL and LPL to the cell surface can create a focal reaction center 
for triacylglycerol hydrolysis thereby releasing fatty acids for cellular uptake by fatty acid transporters such as FATP1 or CD36. 
Alternatively, similar to that proposed for hepatic clearance of apoE-VLDL and chylomicron remnants [57], initial binding to 
HSPG serves to concentrate lipoprotein particles at the cell surface and their uptake is mediated either by direct HSPG inter-
nalization or following their transfer to VLDL-R or LRP.Page 9 of 15
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enriched lipoproteins [36-38]. In liver, HSPG are thought
to either directly internalize bound lipoproteins by hepa-
tocytes or, alternatively, localize lipoproteins to the cell
surface and subsequently transfer particles to LDL recep-
tor family members for endocytosis [57]. In the present
study, we show that heparin effectively competes for
uptake of DiI-labeled apoE-VLDL while RAP has little or
no effect suggesting that, in adipocytes, HSPG are able to
internalize apoE-VLDL independent of LDL receptor fam-
ily members. A direct internalization function by HSPG is
also supported by recent findings from our laboratory
[47] and others [36,37]. Alternatively, HSPG may serve as
a reaction center for triacylglycerol hydrolysis. In addition
to apoE-rich lipoproteins, HSPG are also capable of
binding LPL [39,40]. The binding function of HSPG for
both apoE-rich lipoproteins and LPL can serve to co-local-
ize enzyme and substrate and facilitate release of fatty
acids in proximity of the adipocyte cell surface. Uptake of
these liberated fatty acids can then be accomplished by
fatty acid transport proteins such as CD36 [58] or FATP1
[59].
The identity of this HSPG is currently unknown; however,
its large relative molecular mass and composition con-
taining both heparan and chondroitin sulfates are consist-
ent with the structural properties of the syndecan [60,61]
and perlecan [62] families of proteoglycans. There are
four members to the syndecan family, all of which are
type I transmembrane cell surface molecules. Syndecan-1
is found primarily in epithelial and plasma cells, synde-
can-2 is found in endothelial cells and fibroblasts, synde-
can-3 is expressed in cells of neural crest origin, and
syndecan-4 demonstrates a more ubiquitous distribution,
including adipose tissue [63]. bFGF treatment increases
expression of syndecan-1 in 3T3 cells [64]; however its
presence in adipocytes has not been investigated.
Although the core proteins of the syndecan family are of
modest molecular weight, they are typically modified
with the addition of heparan sulfate glycosaminoglycan
chains near their N-termini and chondroitin sulfate moi-
eties attached more proximal to their membrane spanning
domains, which results in very high molecular masses
when resolved by SDS-PAGE, often >500 kD. Perlecan has
a large complex modular core protein with a molecular
weight of ~400 kD [62,65]. It typically contains three
heparan sulfate chains near its N-terminus, but can also
have chondroitin sulfate substitutions. Perlecan is a
secreted proteoglycan that demonstrates a widespread
distribution as a basement membrane component [66].
As both syndecan and perlecan contain heparan sulfate
glycosaminoglycan chains, they are able to bind LPL with
high affinity [67] and localize its enzymatic activity near
the cell surface thereby serving as a reaction center for tri-
acylglycerol hydrolysis. Moreover, studies have shown
that they can also bind and internalize lipoprotein parti-
cles independent of the classical lipoprotein receptors
[37,38]. We are currently in the process of accurately
quantitating the amounts of heparan and chondroitin
sulfate moieties present on these high molecular weight
proteoglycans and identifying their core protein structure.
Once this information is available, we will be able to con-
firm their role in fatty acid transport and adipocyte hyper-
trophy using expression inhibition procedures and obtain
additional information on their role in adipocyte
physiology.
The availability of circulating triacylglycerol-rich lipopro-
teins for adipocyte utilization and storage relies on
transport of these particles across the endothelial barrier.
Transcytosis of albumin across endothelium has been
shown to occur by a vesicular transport pathway [68-70]
and is a likely mechanism for transport of fatty acid-albu-
min complexes. More recently, members of the LDL recep-
tor family, including VLDL-R [71] and megalin [72,73],
have also been shown to undergo transcytosis across
endothelium and thus provide a mechanism for transport
of triacylglycerol-rich lipoproteins into the tissues. Trans-
port of VLDL across the endothelium is also likely to be
assisted by hydrostatic and osmotic pressures within the
capillary lumen. VLDL and related remnant lipoprotein
particles represent the richest source of triacylglycerols in
the body. The high metabolic requirements of adipocytes
for fatty acids for both storage and utilization make these
triacylglycerol-rich particles a suitable source of available
fatty acids. The presence of a transendothelial transport
mechanism via lipoprotein receptors makes VLDL parti-
cles a logical source of fatty acids for adipose growth.
How HSPG might coordinate its activity with CD36 or
FATP1 for fatty acid uptake or possibly with members of
the LDL receptor family for assisted internalization is
under current investigation. Presently, our results provide
novel findings indicating that cell surface HSPG activity is
necessary for lipid accumulation by adipocytes. It is antic-
ipated that these observations will aid in our understand-
ing of the complex mechanism leading to adipose
hypertrophy and obesity, and provide a novel avenue to




Anti-LRP polyclonal antibody was raised against an 18
amino acid peptide from the cytoplasmic tail of human
LRP [74] and anti-RAP polyclonal antibody was raised
against a recombinant RAP-GST fusion protein as
described [75]. Anti-VLDL-R polyclonal antibody was a
generous gift from Dr. Dudley Strickland (School of
Medicine, University of Maryland, Baltimore). Anti-Page 10 of 15
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purchased from American Type Culture Collection (Man-
assas, VA) anti-leptin polyclonal antibody was purchased
from Chemicon (Temecula, CA), and anti-CD36 polyclo-
nal antibody (H-300) was obtained from Santa Cruz Bio-
technology (Santa Cruz, CA). Dexamethasone, 3-isobutyl-
1-methylxanthine and insulin were obtained from Sigma-
Aldrich (St. Louis, MO). 35SO4 were purchased from MP
Biomedicals (Irvine, CA). p-nitrophenyl-β-D-xylopyrano-
side and 4-methylumbelliferyl-β-D-xylopyranoside were
from Calbiochem (La Jolla, CA). Heparin, heparinase I,
chondroitinase ABC, p-nitrophenylbutyrate, lipoprotein
lipase, and Oil Red O were purchased from Sigma-
Aldrich. Optiprep was from Greiner Bio-One (Longwood,
FL). DiI (1,1'-dictadecyl-3,3,3',3'-tetramethylindocarbo-
cyanine perchlorate) was purchased from Molecular
Probes (Eugene, OR). Apolipoprotein E was obtained
from Calbiochem. RAP-GST fusion protein was purified
as previously described [76]. Tissue culture plastics were
purchased from Corning (Corning, NY) or Greiner Bio-
One. Buffers, salts, and detergents were obtained from
either Sigma-Aldrich or Calbiochem.
Cell culture and adipocyte differentiation
3T3-L1 cells were obtained from American Type Culture
Collection (Manassas, VA) and grown in Dulbecco's
modified Eagle's medium (DMEM) (Invitrogen, Carlsbad,
CA) supplemented with 10% (v/v) fetal calf serum (Irvine
Scientific, Santa Ana, CA), 1 mM sodium pyruvate, 100
µg/ml streptomycin sulfate, and 100 units/ml penicillin.
Cells were cultured at 37°C with 5% CO2 and passaged
twice weekly. To differentiate 3T3-L1 cells into adipocytes,
cells were incubated with 100 ng/ml dexamethasone, 100
µg/ml 3-isobutyl-1-methylxanthine, and 1 µg/ml insulin
for 4 days, followed by 1 µg/ml insulin for an additional
4–8 days.
Immunoblotting
Cell lysates were prepared with 20 mM Tris pH 7.4, 150
mM NaCl (TBS) containing 1% (v/v) Triton-X100. For
leptin, culture supernatants were concentrated by mixing
with 3 volumes ice cold acetone, incubating at -20°C for
1 h, followed by centrifugation at 10,000 × g at 4°C for 15
min. Protein pellets were resuspended with SDS-PAGE
sample buffer supplemented with 2% (v/v) β-mercap-
toethanol. Proteins were then separated by SDS-PAGE
and transferred to Immobilon-P (Millipore, Billerica, MA)
using a wet tank transfer system (BioRad, Hercules, CA).
Membranes were blocked with TBS, 0.1% (v/v) Tween-20,
5% (w/v) non-fat dry milk for 20 minutes at 23°C and
incubated with the indicated antibody for 2 h at 23°C.
Membranes were washed three times (10 min each) with
TBS, 0.1% (v/v) Tween-20, and bound antibodies were
detected with species-specific HRP-conjugated secondary
antibodies (1:3000, BioRad) followed by chemilumines-
cence detection according to the manufacturer's instruc-
tions (Pierce, Rockford, IL). Images were captured using a
Syngene GeneGnome system equipped with a Peltier-
cooled 16-bit CCD camera and saturation detection.
Densitometric analysis was performed using Scion Image,
version 4.0.2.
125I-RAP cell surface 4°C binding assay
RAP-GST was purified [76] and labeled with Na125I as pre-
viously described [77]. Differentiated 3T3-L1 cells were
grown on tissue culture plates precoated with 1% (w/v)
gelatin and incubated with 125I-RAP-GST (500 ng/ml)
diluted into 20 mM Hepes, pH 7.4, 150 mM NaCl, 2 mM
CaCl2, 1% (w/v) bovine serum albumin (buffer A) at 4°C
for 3 h in the presence or absence of a 50-fold molar
excess of unlabeled RAP-GST. Unbound 125I-RAP-GST was
removed by rinsing cells three times with cold buffer A
after which cells with bound ligand were solubilized with
0.1 N NaOH. Solubilized proteins were added to EcoL-
ume (ICN Biomedicals, Costa Mesa, CA) and subjected to
scintillation counting (Packard Tri-Carb 1600CA, 73%
efficiency for 125I). Results were normalized to total cellu-
lar protein (BCA Protein Assay, Pierce, Rockford, IL). Spe-
cificity was determined as the difference between total
binding (without competition) and non-specific binding
(non-competable) [78]. The actual amount of ligand
bound to cells was calculated as cpm ÷ the specific activity
of 125I-labeled ligand. All data points represent averages of
duplicates or triplicates with standard errors of <5%.
37°C ligand degradation assay
Differentiated 3T3-L1 cells were incubated at 37°C/5%
CO2 for 3 h with 500 ng/ml 125I-RAP-GST diluted into
DMEM containing 1% (w/v) bovine serum albumin in
the presence or absence of a 50-fold molar excess of unla-
beled RAP-GST. Media was then removed and processed
for trichloroacetic acid (TCA) precipitation [75]. TCA-sol-
uble material was added to EcoLume and subjected to
scintillation counting. Degradation was calculated as
TCA-soluble cpm ÷ specific activity of the radioiodinated
ligand.
35SO4 incorporation and proteoglycan analysis
3T3-L1 pre-adipocytes and differentiated adipocytes
grown in 100 mm tissue culture dishes were incubated
with sulfate-free DME containing 10% (v/v) fetal calf
serum and 125 µCi/ml Na2 35SO4 for 20 h at 37°C/5%
CO2. Cells were detached by incubating with phosphate
buffered saline containing 5 mM EDTA for 20 min at
23°C. Following centrifugation to pellet cells (1000 × g,
4°C, 10 min), they were lysed by incubation with solubi-
lization buffer (100 mM Tris, pH 7.5, 150 mM NaCl, 8 M
urea) for 1 h at 4°C. Insoluble material was removed by
centrifugation (10,000 × g, 4°C, 5 min) and supernatant
was batch adsorbed onto 0.5 ml Macro-Prep DEAE Sup-Page 11 of 15
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with gentle agitation for 1 h at 4°C. DEAE resin was
applied to a 1.0 cm × 5.0 cm column and washed with 10
column volumes solubilization buffer followed by 10 col-
umn volumes 100 mM Tris, pH 7.5, 150 mM NaCl.
Bound proteins were eluted with 100 mM Tris, pH 7.5, 1.0
M NaCl and 120 µl fractions were collected. Fifteen µl
from each fraction was mixed with 3 ml EcoLume and
subjected to scintillation counting. Peak fractions from
DEAE enrichment of proteoglycans obtained from labeled
differentiated adipocytes (fraction no. 3 and 4, Fig. 3A)
were pooled and diluted with dH2O to adjust to 150 mM
NaCl. This preparation was then incubated with or with-
out either heparinase I (5 units/ml) or chondroitinase
ABC (5 units/ml) or both for 20 h at 37°C. The material
was applied to a 1.0 cm × 12 cm Sephacryl S-200 HR
(Amersham Biosciences, Piscataway, NJ) gel filtration col-
umn and eluted with 20 mM Tris, pH 7.4, 150 mM NaCl.
350 µl fractions were collected of which 200 µl was mixed
with 3 ml EcoLume and analyzed by scintillation
counting.
Preparation of DiI-labeled apoE-VLDL
New Zealand White rabbits were placed on a high-fat
chow diet (10% peanut oil/1% cholesterol) for a mini-
mum of 4 d, blood was drawn into in 1 mM EDTA and
centrifuged at 2000 × g, 15 min to remove cells. Chylom-
icrons were floated by centrifuging plasma at 100,000 × g
for 10 min and removed by pipetting. Plasma was then
mixed with OptiPrep™ (12% iodixanol final concentra-
tion) and centrifuged at 350,000 × g for 3 h (SW55Ti
rotor) with slow acceleration and deceleration. VLDL par-
ticles (density of 1.006 g/ml) were removed from the top
of the gradient by pipetting. Purified VLDL was analyzed
by SDS-PAGE and Coomassie R staining to confirm the
presence of apoB100 (515 kD) and apoE (35 kD). Animal
protocol (#2032) was approved by the University of New
Mexico, Health Sciences Center Laboratory Animal Care
and Use Committee. For DiI labeling, a working stock of
3 mg/ml was made in dimethylsulfoxide and 0.15 mg was
slowly added to 1.67 mg VLDL (in 1.9 ml) with vortexing
to rapidly mix. The mixture was then wrapped in foil and
incubated for 8 h at 37°C. Unbound DiI was removed
from DiI-labeled VLDL by OptiPrep gradient centrifuga-
tion as described above.
DiI-labeled apoE-VLDL uptake assay
3T3-L1 cells were plated on glass coverslips and incubated
with differentiation reagents as described above. After
conversion to mature adipocytes, cells were rinsed twice
with DMEM and incubated with DiI-VLDL (4 µg/ml) and
apolipoprotein E (3 µg/ml) diluted into DMEM in the
presence or absence of either heparin (500 µg/ml) or RAP-
GST (50 µg/ml). After 3 h at 37°C, cells were rinsed with
phosphate buffered saline, fixed with 1.5% (w/v) parafor-
maldehyde for 30 min, and mounted in Gelvatol (Air
Products, Allentown, PA) containing 1 mg/ml p-phe-
nylenediamine. Cells were observed with a Zeiss Axioskop
microscope equipped for epifluorescence. Images were
capture with a Hamamatsu digital/video camera and
AxioVision software.
LPL activity
Treated and non-treated 3T3-L1 cells (as indicated in fig-
ure legends) were cultured overnight in serum-free DMEM
without phenol red. Media was removed and combined
with an equal volume of 100 mM sodium phosphate
buffer, pH 7.2, 150 mM NaCl, 0.5% (v/v) Triton-X100. p-
nitrophenyl butyrate in acetonitrile was added to a final
concentration of 0.5 mM and absorbance at 400 nm was
recorded every 10 s for 5 min using a Genesys UV Spectro-
photometer. A standard curve for LPL activity was gener-
ated by plotting absorbance values obtained with varying
concentration of purified LPL (from bovine milk). Quan-
titation of LPL activity in the individual media samples
was determined from the standard curve.
Oil Red O staining and quantitation
Cells were fixed with 10% (v/v) formaldehyde in phos-
phate buffered saline for 1 h at 23°C, rinsed twice with
water, then stained for 2 h at 23°C with 0.1% (w/v) Oil
Red O in 75% (v/v) isopropanol, followed by rinsing
twice with water to remove unincorporated dye. Stained
cells were viewed and photographed using a Zeiss Axio-
Vert microscope with phase contrast optics and
Hamamatsu digital/video camera. For quantitation, cells
were dried for 2 h at 37°C, followed by incubation with
100% isopropanol for 15 m at 23°C to extract bound dye.
Solubilized dye was then quantitated by spectrophotome-
try in a BioRad Model 680 Microplate Reader by measur-
ing absorbance at 510 nm. Statistical significance was
determined by performing a paired t-test.
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